Literature DB >> 11091108

PET physiological measurements using constant infusion.

R E Carson1.   

Abstract

A wide range of study designs can be used with positron emission tomography methods to provide quantitative measurements of physiological parameters. While bolus injection of tracer is the conventional approach, use of combined bolus plus constant infusion provides a number of advantages for receptor-binding tracers. Of recent interest is the use of this approach to dynamically follow the displacement of tracer during in vivo changes in neurotransmitter concentrations. This paper provides an overview of the tradeoffs in using bolus/infusion methods versus conventional bolus injection for receptor binding studies.

Mesh:

Substances:

Year:  2000        PMID: 11091108     DOI: 10.1016/s0969-8051(00)00138-4

Source DB:  PubMed          Journal:  Nucl Med Biol        ISSN: 0969-8051            Impact factor:   2.408


  35 in total

Review 1.  Determination of the Input Function at the Entry of the Tissue of Interest and Its Impact on PET Kinetic Modeling Parameters.

Authors:  M'hamed Bentourkia
Journal:  Mol Imaging Biol       Date:  2015-12       Impact factor: 3.488

2.  In vivo biased agonism at 5-HT1A receptors: characterisation by simultaneous PET/MR imaging.

Authors:  Benjamin Vidal; Sylvain Fieux; Jérôme Redouté; Marjorie Villien; Frédéric Bonnefoi; Didier Le Bars; Adrian Newman-Tancredi; Nicolas Costes; Luc Zimmer
Journal:  Neuropsychopharmacology       Date:  2018-07-06       Impact factor: 7.853

3.  Speech-induced striatal dopamine release is left lateralized and coupled to functional striatal circuits in healthy humans: a combined PET, fMRI and DTI study.

Authors:  Kristina Simonyan; Peter Herscovitch; Barry Horwitz
Journal:  Neuroimage       Date:  2012-12-28       Impact factor: 6.556

4.  Cigarette smoking saturates brain alpha 4 beta 2 nicotinic acetylcholine receptors.

Authors:  Arthur L Brody; Mark A Mandelkern; Edythe D London; Richard E Olmstead; Judah Farahi; David Scheibal; Jennifer Jou; Valerie Allen; Emmanuelle Tiongson; Svetlana I Chefer; Andrei O Koren; Alexey G Mukhin
Journal:  Arch Gen Psychiatry       Date:  2006-08

5.  Assessing the sensitivity of [¹¹C]p943, a novel 5-HT1B radioligand, to endogenous serotonin release.

Authors:  Kelly P Cosgrove; Tracy Kloczynski; Nabeel Nabulsi; David Weinzimmer; Shu-Fei Lin; Julie K Staley; Zubin Bhagwagar; Richard E Carson
Journal:  Synapse       Date:  2011-05-03       Impact factor: 2.562

6.  Multimodality imaging of blood-brain barrier impairment during epileptogenesis.

Authors:  Heike Breuer; Martin Meier; Sophie Schneefeld; Wolfgang Härtig; Alexander Wittneben; Martin Märkel; Tobias L Ross; Frank M Bengel; Marion Bankstahl; Jens P Bankstahl
Journal:  J Cereb Blood Flow Metab       Date:  2016-01-01       Impact factor: 6.200

Review 7.  Advances in simultaneous PET/MR for imaging neuroreceptor function.

Authors:  Christin Y Sander; Hanne D Hansen; Hsiao-Ying Wey
Journal:  J Cereb Blood Flow Metab       Date:  2020-03-13       Impact factor: 6.200

8.  Simultaneous PET/MRI Imaging During Mouse Cerebral Hypoxia-ischemia.

Authors:  Yu Ouyang; Martin S Judenhofer; Jeffrey H Walton; Jan Marik; Simon P Williams; Simon R Cherry
Journal:  J Vis Exp       Date:  2015-09-20       Impact factor: 1.355

9.  Intravenous ethanol increases dopamine release in the ventral striatum in humans: PET study using bolus-plus-infusion administration of [(11)C]raclopride.

Authors:  Sargo Aalto; Kimmo Ingman; Kati Alakurtti; Valtteri Kaasinen; Jussi Virkkala; Kjell Någren; Juha O Rinne; Harry Scheinin
Journal:  J Cereb Blood Flow Metab       Date:  2014-12-10       Impact factor: 6.200

10.  Kinetic analysis of the metabotropic glutamate subtype 5 tracer [(18)F]FPEB in bolus and bolus-plus-constant-infusion studies in humans.

Authors:  Jenna M Sullivan; Keunpoong Lim; David Labaree; Shu-Fei Lin; Timothy J McCarthy; John P Seibyl; Gilles Tamagnan; Yiyun Huang; Richard E Carson; Yu-Shin Ding; Evan D Morris
Journal:  J Cereb Blood Flow Metab       Date:  2012-12-19       Impact factor: 6.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.